News

Oct 15,2020

Apexigen’s APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer

Oct 06,2020

C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 01,2020

C4 Therapeutics Announces Pricing of an Upsized Initial Public Offering

Sep 24,2020

OncoImmune’s SACCOVID™ (CD24Fc) Exhibits Superb Therapeutic Efficacy—A Potential Breakthrough in Treating Severe and Critical COVID-19

Sep 23,2020

OncoImmune Launches First-in-human Clinical Trial for ONC-392 – The anti-CTLA-4 Antibody that Preserves CTLA4 Recycling for Safer and More Effective Immunotherapy

Sep 16,2020

Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial Evaluating IO-202, a First-In-Class Antibody for the Treatment of Acute Myeloid Leukemia

Sep 06,2020

Ansun Biopharma and HJB Enter Strategic Agreement on Biologics CMC Development and Manufacturing Partnership

Jun 17,2020

C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept and to Advance Proprietary Platform

End of content

No more pages to load